News Changing Faces: biopharma hires from November 2022 The month of November saw a number of notable hires and personnel moves in biotech and
News Atriva takes MEK inhibitor into phase 2 for COVID-19 Atriva Therapeutics is starting a phase 2 trial of its MEK inhibitor ATR-002 in patients with coronavirus infections, saying the drug could help prevent patients progressing to
News Kidney biotech R1's $78m debut, and other biofinancings Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
